TR Secures Strategic Investment from Daewoong Pharmaceutical and Naver

TR, a South Korean digital medical device company, has signed strategic investment agreements with Daewoong Pharmaceutical and Naver.

The deal with Daewoong Pharmaceutical includes a distribution agreement for TR’s flagship product, The Spirokit, a digital spirometry device. Through Daewoong’s extensive domestic sales network — one of the largest in the country spanning hospitals and clinics — TR expects to meaningfully grow its share of the primary care market.

The Naver partnership carries significant weight on the technology side. TR plans to integrate its pulmonary function data analysis and LLM-based interpretation system with Naver Cloud and the generative AI platform HyperCLOVA X. By combining Naver’s cloud infrastructure with TR’s proprietary respiratory diagnostic algorithms, the two companies aim to build an advanced real-time AI-assisted interpretation system.

“We are deeply honored to forge strategic partnerships with leading companies in their respective fields,” said Byungsoo Kim, CEO of TR. “This investment is a recognition of our technology and growth potential, and we will use it to further strengthen our position in South Korea’s respiratory diagnostics market.”

TR develops and commercializes its own respiratory medical devices in a domestic market that has long been dominated by imported products. The company is actively pursuing expansion into Asia — including Vietnam and Kazakhstan — as well as the Middle East and Latin America.